MoonLake Immunotherapeutics

It's my pleasure to welcome here as well two of my colleagues, our CEO and co-founder, George Santos da Silva, our CSO and co-founder, Professor Christian Reich, and we are also joined here by two of the leading KOLs, Professor Ken Gordon and Professor Joseph Merola, who are joining us here to reflect on us with the data on the opportunity of simulation.

sections.

On the one hand, we will present the cirrhotic arthritis 24-weeks data. So we have a whole section dedicated to cirrhotic arthritis, one of our lead indications for sunolocumab. Then we have a whole section dedicated to the opportunity in hydrodinitis superativa, a couple of important and relevant updates also on that front. And then in the third main section, we will talk a little bit about the new frontiers for sunolocumab. Here you see the disclaimer on forward-looking statements, so please acknowledge the disclaimer. You will also have the opportunity to submit questions through the Q&A function in the webcast. Here in the room, towards the end, we will have time for a couple of questions, so then please raise your hand.